Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Debt to Equity (2020 - 2025)

Bioventus' Debt to Equity history spans 6 years, with the latest figure at $1.52 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 33.21% year-over-year to $1.52; the TTM value through Dec 2025 reached $1.52, down 33.21%, while the annual FY2025 figure was $1.52, 33.21% down from the prior year.
  • Debt to Equity reached $1.52 in Q4 2025 per BVS's latest filing, down from $1.94 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.27 in Q4 2024 to a low of $0.59 in Q4 2021.
  • Average Debt to Equity over 5 years is $1.41, with a median of $1.66 recorded in 2023.
  • Peak YoY movement for Debt to Equity: crashed 54.95% in 2021, then surged 198.86% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $0.59 in 2021, then soared by 72.3% to $1.01 in 2022, then surged by 63.65% to $1.66 in 2023, then skyrocketed by 36.69% to $2.27 in 2024, then tumbled by 33.21% to $1.52 in 2025.
  • Per Business Quant, the three most recent readings for BVS's Debt to Equity are $1.52 (Q4 2025), $1.94 (Q3 2025), and $1.7 (Q2 2025).